Cholestatic pruritus is one of the most common complaints in patients with liver diseases and intra-or posthepatic cholestasis. The mechanisms of cholestatic pruritus remain poorly understood although multiple factors are considered to participate in the pathogenesis of cholestatic pruritus. Recent exciting studies have discovered several G-protein coupled receptors (GPCRs) and endogenous chemical ligands that play critical roles in mediating cholestatic pruritus in animal models and patients. These new findings have provided novel insights into the molecular and cellular mechanisms of cholestatic pruritus and improved our understanding of the etiology and treatment for the condition.
Cholestatic pruritus is a serious clinical problem for patients with cholestatic liver diseases thought to be caused by impaired bile acid secretion. Featuring the symptom of severe itch, the condition accompanies a variety of disorders, including but not limited to liver diseases, renal diseases, and viral infections. Common causes of cholestatic pruritus in adults include primary biliary cirrhosis (PBC), intrahepatic cholestasis of pregnancy (ICP), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH) [1] . The condition can become unmanageable by traditional medical treatments, and in extreme cases can serve as justifying grounds for liver transplantations even when liver failure is not imminent. A traditional theory holds that cholestatic pruritus is mediated by significantly increased bile acids in the serum of patients that ultimately form deposits and induce itch in the skin, although the molecular basis of bile acid sensing in the itch pathway remains unclear. A major complication with this theory lies in the observation that there does not appear to be a particularly strong, if any, correlation between bile acid concentrations in the bloodstream and pruritus severity [2] .
Bile acids have multiple molecular targets, including both nuclear and membrane-bound receptors in various cell types. Alemi et al recently demonstrated that the bile acid-activated G protein-coupled receptor (GPCR) TGR5, also known as GPR131 and encoded by GPBAR1, mediated bile acid-induced pruritus and analgesia in tandem with the transient receptor potential cation channel, member A1 (TRPA1) channel [3, 4] . TRPA1 and the capsaicin receptor TRPV1 have been well-established itch mediators participating in both histaminergic and non-histaminergic RESEARCH HIGHLIGHT pruritus [5] . TGR5 was expressed by TRPV1 + and TRPA1 + dorsal root ganglion (DRG) neurons as well as neurons expressing the itch neuromediator gastrin-releasing peptide (GRP). Deoxycholic acid (DCA), a major bile acid, increased the excitability of DRG neurons from wild-type but not TGR5 knockout mice. Treatments with DCA or other bile acids that also increase action potential firing in DRG neurons evoked neuropeptide release from rat spinal cord and elicited a TGR5-dependent scratching response when applied intradermally [3] . Furthermore, pharmacological inhibition or genetic ablation of the TRPA1 channel function prevented the bile acid-stimulated release of pruritogenic agents and subsequent scratching.
The nuclear receptor farnesoid X receptor (FXR), a bile sensor extensively expressed in hepatocytes, has been suggested to also play a role in cholestatic pruritus [6] . As part of a detoxification system designed to shield the liver from the adverse effects of excessive bile acids during cholestasis, FXR activation has been shown to create or intensify pruritic symptoms in patients with cholestasis. Cipriani et al recently headed a study that observed the pharmacological effects of a non-bile acid steroidal dual ligand for both FXR and GPBAR1, BAR502, in rodent models for cholestatic pruritus. While it was observed that injection of BAR502 induced GPBAR1-dependent itching responses in naïve mice, repeated challenges of the test subjects with additional doses of the agonist were met with diminished pruritogenic responses. In mice suffering from cholestatic conditions, furthermore, administration of GPBAR1 agonists wholly failed to induce itching behavior. The rapid desensitization observed during repeated injections of GPBAR1 agonist along with the deactivation of the itch pathway in rodent cholestatic models seem to account for the lack of correlation between itching severity and total bile acid concentrations in cholestatic patients. In addition, the same experiment revealed that the ablation of the GPBAR1 gene exacerbates the liver damage resulting from pruritus, while the administration of BAR502 attenuates cholestatic damage and increases survival rates, all without inducing itch [6] . This study suggests that the molecular agents of pruritus in cholestatic conditions may serve vital roles in the management of said cholestasis.
Interestingly, bile acid-elicited scratching was also significantly reduced in mice treated with a GRP receptor (GRPR) antagonist or the μ-opioid receptor antagonist naltrexone, suggesting that GRP and endogenous opioids could be the downstream mediators of TGR5-ediated pruritus. In fact, opioids have long been proposed as an alternative mediator of cholestatic pruritus and naloxone has been used to treat patients with cholestatic pruritus [7, 8] . Due to their role in the reduction of pain signaling, the release of opioids has proven capable of inducing itch following activation of μ-opioid receptors. While an increase in opioid concentration has indeed been observed in cholestatic patients, there is once again no perceived correlation between opioid amounts and the extent of pruritus. Opioids may well retain a role of key importance in the mechanism of cholestatic pruritus; the ability of naltrexone and other μ-opioid receptor antagonists to attenuate itching symptoms, however, may also simply be explained by the intrinsic and intimate connection between the signaling pathways of pain and itch [9] . Recently, lysophosphatidic acid (LPA) has also been proposed as the mediator of cholestatic pruritus based on clinical findings that the lysophospholipase autotaxin, which generates LPA from lysophosphatidylcholine (LPC), was increased in sera from patients with cholestatic pruritus and that the activity of autotaxin (ATX) in blood was correlated with itch intensity in cholestatic patients [10] . This correlation between autotaxin levels and itch intensity stands in stark contrast to patterns observed with serum bile salts, where no such relationship was present. Originally identified as a factor in cell motility that was overexpressed in sundry tumors and involved in the development of metastases, autotaxin has been found to serve as a compelling indicator of cholestatic pruritus severity and therapeutic intervention effectiveness [11] . Patients with PBC undergoing nasobiliary drainage treatment exhibited simultaneous decreases in itch intensity and autotaxin activity followed by returns to previous levels after intervention; this further evidences the role of ATX and LPA in cholestatic pruritus [10] . Further studies showed that serum ATX levels only increased in patients with cholestatic pruritus but not pruritus of other origins, such as atopic dermatitis, pruritus of uremia, or Hodgkin's disease. Moreover, pharmacological inhibition of ATX activity reversibly reduced itch intensity in severe cholestatic pruritus [11] . Intradermal injection of LPA to mice consistently elicited a scratching response that was reduced by antihistamines but not affected by genetic ablation of the TGR5, suggesting distinct pathways are involved in the generation of itch by LPA and bile acids [3, 12] . These discoveries pave the road for the development of novel antipruritic treatments and drugs that might function by inhibiting ATX activity or by blocking LPA receptors.
The cellular basis of LPA-induced itch is intriguing since LPA acts on many targets, including a 6-membered family of GPCRs (LPA1-6) as well as the pain-and itch-sensing TRPV1 channels [13] . LPA is a critical endogenous lipid mediator of neuropathic pain through multiple LPA receptors including LPAR1, LPAR3, and LPAR5 [14] [15] [16] [17] . LPAR3 signaling in spinal microglia in response to nerve injury results in more production of LPA and LPAR1 signaling in schwann cells leading to myelin degradation and axon sprouting, which initiates neuropathic pain [18] . Interestingly, the Aβ and Aδ but not TRPV1-positive C fibers are essential to LPA-induced neuropathic pain. On the other hand, TRPV1 expression is upregulated in the Aβ and Aδ fibers, which could contribute to the neuropathic pain response [19] . Besides activation of G-protein-coupled LPA receptors, LPA was also reported to sensitize TRPV1 through LPA1/protein kinase Cε (PKCε) signaling and produce bone cancer pain [20] . Additionally, Nieto-Posadas et al showed that LPA was a direct activator of TRPV1 by interacting with a C-terminal binding site of the TRPV1 to drive the channel open, which produces acute nocifensive responses [13] .
Although exogenously applied bile acids and LPA can induce scratching responses, it is important to note that patients associated with cholestatic pruritus might have many more changes in the itch transduction pathway including skin, primary sensory neurons, and complex neural circuits in the spinal cord. Therefore, animal models of cholestatic pruritus are urgently needed to investigate the pathophysiology of cholestatic pruritus. Numerous studies have already been conducted which utilize naïve rodent subjects to identify mediators of the disease; the weakness of these experiments, however, lies in the fact that their conditions cannot accurately reflect the physiological environment characteristic of actual cholestatic pruritus. While artificial stimulation of protein channels may induce itch in healthy mice, this does not allow for the conclusion that the aforementioned channels are responsible for pruritic symptoms under the vastly divergent setting of a diseased system. This is directly reflected by the discrepancy between two studies focusing on the roles of TGR5 pathway in the pathogenesis of cholestatic pruritus: one study labeled the TGR5 channel as a key mediator for pruritus induced by intradermal injection of bile acids [3] but the other study showed the deactivation of the TGR5 pathway in genuinely cholestatic conditions [6] . It is for this reason that inquiry into the topic of cholestatic pruritus is in dire need of a shift towards cholestatic models that can authentically portray the pathophysiology present in real-world cases of the condition and away from artificial and imprecise portraits in naïve subjects. These models are, at present, scarce in rodents and virtually non-existent among mammals of other orders. New cholestatic animal models must be pioneered and developed as the next step towards uncovering the underlying mechanisms behind and mediators of cholestatic pruritus.
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